Exact Sciences Bundle
Who Owns Exact Sciences?
Exact Sciences, a pioneer in cancer diagnostics, transitioned to public ownership via its 2001 IPO. Founded in 1995, the company aimed to revolutionize cancer detection, starting with colorectal cancer screening.
Today, Exact Sciences is a leader in cancer screening and diagnostics, known for products like Cologuard and Oncotype DX. As of June 2025, its market capitalization stands at approximately $10.1 billion, with a significant portion held by institutional investors.
The ownership landscape of Exact Sciences is dominated by institutional investors, reflecting its substantial presence in the biotechnology and diagnostics sector. Understanding these stakeholders is key to grasping the company's strategic direction and market influence. For a deeper dive into the company's operational environment, consider the Exact Sciences PESTEL Analysis.
Who Founded Exact Sciences?
Exact Sciences was co-founded in 1995 by engineer Stanley Lapidus and Anthony P. Shuber, aiming to develop a non-invasive colorectal cancer screening method. The company's foundational patent for stool sample collection was approved in 1998, building on research from Johns Hopkins University. While exact initial equity percentages are not public, their pivotal roles suggest significant early ownership and influence.
| Founder | Role | Initial Involvement |
|---|---|---|
| Stanley Lapidus | Co-Founder, Engineer | Visionary for non-invasive screening |
| Anthony P. Shuber | Co-Founder | Shared vision with Lapidus |
Founding Vision
The company's inception was driven by a shared goal to revolutionize colorectal cancer detection through a non-invasive approach.
Key Patent
A crucial patent for a stool sample collection method was secured in 1998, forming the technological basis for early development.
Early Funding
An initial venture capital round of $6.7 million was vital for navigating the challenging research and development phases.
IPO and Market Challenges
The company went public on NASDAQ in February 2001. Early public years presented market difficulties, with share prices falling below $1 at one point.
Research Foundation
The company's technological groundwork was significantly influenced by research originating from Johns Hopkins University.
Ownership Transparency
Specific details regarding founders' initial equity percentages and early ownership disputes are not readily available in public records.
The early stages of Exact Sciences involved significant investment, with a $6.7 million venture capital round being critical for its survival and progress. This funding supported the intensive research and development required to bring their innovative screening technology to fruition. The company's transition to a publicly traded entity occurred with its IPO on the NASDAQ stock market in February 2001. Despite this milestone, the initial public period was marked by market volatility, with the stock price experiencing a significant decline. Understanding the intricacies of early Exact Sciences ownership is key to grasping its trajectory, and for a deeper dive into its strategic path, one might consider the Marketing Strategy of Exact Sciences.
Key Milestones in Early Ownership
The formative years of Exact Sciences were characterized by foundational patent acquisition, early-stage funding, and a challenging public market debut.
- Founding by Stanley Lapidus and Anthony P. Shuber in 1995.
- Securing of a foundational patent in 1998.
- Initial venture capital funding of $6.7 million.
- Initial Public Offering (IPO) on NASDAQ in February 2001.
- Navigating early market challenges post-IPO.
Exact Sciences SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Exact Sciences’s Ownership Changed Over Time?
The ownership structure of Exact Sciences has evolved significantly since its IPO in February 2001, raising $56 million. This transition to a public entity allowed for a broad spectrum of investors to participate, fundamentally altering who owns Exact Sciences.
| Shareholder Type | Percentage (March 2025) | Percentage (April 2024) |
| Institutional Investors | 97.53% | 89% |
| Insider Ownership | 1.04% | N/A |
Institutional investors are the dominant force in Exact Sciences' ownership, holding approximately 97.53% of the company's outstanding shares as of March 2025. This figure represents a substantial increase from roughly 89% in April 2024, highlighting the growing influence of large investment firms. Among the key institutional shareholders are Fmr Llc, Capital World Investors, and The Vanguard Group. Other significant holders include BlackRock, Inc., Wellington Management Group Llp, State Street Corp, and T. Rowe Price Group, Inc. These entities wield considerable power in shaping the company's strategic direction and corporate governance. Insider ownership, which includes shares held by executives and board members, stood at about 1.04% in March 2025. For instance, CEO Kevin Conroy held approximately 0.8% of the company's shares as of April 2024. Edwin M. Kania Jr. is also a notable individual shareholder, possessing 1.38 million shares, which equates to 0.73% of the company. Understanding the Exact Sciences shareholder base is crucial for grasping its market dynamics.
Key Stakeholders in Exact Sciences Ownership
Institutional investors are the primary owners of Exact Sciences, with their stake growing significantly. This concentration of ownership among large firms impacts the company's strategic decisions.
- Fmr Llc
- Capital World Investors
- The Vanguard Group
- BlackRock, Inc.
- Wellington Management Group Llp
- State Street Corp
- T. Rowe Price Group, Inc.
Strategic acquisitions have played a pivotal role in reshaping the ownership landscape and market position of Exact Sciences. The company's acquisitions of Genomic Health in 2019, followed by Paradigm Diagnostics, Viomics, and Thrive Earlier Detection Corp. in 2020, significantly expanded its product offerings and market reach. These strategic moves have indirectly influenced investor interest and the overall valuation of the company, contributing to the current Exact Sciences stock ownership patterns. Analyzing these acquisitions provides insight into the Competitors Landscape of Exact Sciences and its growth trajectory, which in turn affects its shareholder base.
Exact Sciences PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Exact Sciences’s Board?
The Board of Directors at Exact Sciences is instrumental in guiding the company's strategic direction and governance. As of the June 12, 2025, Annual Meeting, seven directors were elected, with Kevin Conroy serving as both CEO and Chairman of the Board. This structure ensures a blend of insider knowledge and independent oversight.
| Director Name | Role | Key Affiliation/Background |
|---|---|---|
| Kevin Conroy | Chairman of the Board & CEO | Company Leadership |
| Dr. David E.I. Pyott | Lead Independent Director | Extensive experience in healthcare leadership |
| Dr. Paul J. Brown | Director | Medical and business expertise |
| Dr. Jeffrey L. Emmen | Director | Scientific and operational background |
| Dr. Brenda J. Freeman | Director | Marketing and media industry leadership |
| Dr. David R. King | Director | Financial and strategic management experience |
| Dr. Patricia A. Maryland | Director | Healthcare management and public health focus |
Exact Sciences utilizes a straightforward voting structure where each share of common stock carries one vote, reinforcing the principle of equal shareholder rights. The company's declassified board means all directors stand for election annually, fostering greater accountability to the Exact Sciences shareholders. In situations without opposition, directors are confirmed if they receive more 'for' votes than 'withheld' votes, a common practice in corporate governance to ensure board effectiveness.
Governance and Shareholder Alignment
Recent corporate actions demonstrate a commitment to aligning stakeholder interests with company performance. These initiatives are designed to foster long-term value creation and enhance the overall Exact Sciences ownership experience.
- Approval of the 2025 Omnibus Long-Term Incentive Plan.
- Amendment to the Employee Stock Purchase Plan.
- Ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025.
- Advisory vote on executive compensation.
Understanding the Target Market of Exact Sciences is also influenced by who holds significant voting power. While the exact percentage of Exact Sciences stock ownership by institutional investors fluctuates, they typically represent a substantial portion of the shareholder base. This concentration of ownership among major institutional holders often means they have a significant voice in board elections and major corporate decisions, impacting the overall Exact Sciences company structure and direction. The company's commitment to transparency in Exact Sciences ownership information is vital for investors seeking to understand who controls Exact Sciences.
Exact Sciences Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Exact Sciences’s Ownership Landscape?
Over the past year, Exact Sciences has seen a significant increase in institutional ownership, climbing from approximately 89% in April 2024 to 97.53% by March 2025. This trend highlights growing confidence from major investment firms in the company's trajectory and stability.
| Ownership Metric | Value | Date |
| Institutional Ownership | 97.53% | March 2025 |
| Institutional Ownership | 89% | April 2024 |
| Share Price | $52.34 | June 18, 2025 |
| Share Price Change (YoY) | 18.95% | June 20, 2024 - June 18, 2025 |
Exact Sciences reported robust financial performance in 2024, with total revenue reaching $2.76 billion, a 10% increase from the previous year. This growth has bolstered investor confidence, and the company anticipates total revenue for 2025 to fall between $3.025 billion and $3.085 billion. Key recent investments include Nuveen LLC's acquisition of over 1 million shares, valued at approximately $45.33 million, and DLD Asset Management LP's purchase of 78,500 shares, worth around $3.398 million, both occurring in the first quarter of 2025. These transactions underscore the increasing interest from significant financial entities in Exact Sciences ownership.
Institutional Investor Activity
Nuveen LLC and DLD Asset Management LP have recently increased their stakes in Exact Sciences. These investments reflect positive sentiment towards the company's market position and future prospects.
CEO's Commitment to Ownership
CEO Kevin Conroy has demonstrated strong conviction in the company's value. His personal investment of $1.0 million in company stock within the last year signals his optimism and alignment with shareholder interests.
Shareholder Alignment Initiatives
Recent shareholder actions, such as the approval of the 2025 Omnibus Long-Term Incentive Plan, aim to further align employee and director interests with those of shareholders. This focus on shared goals is crucial for long-term value creation.
Future Growth and Product Pipeline
The company is set to launch three new cancer tests in 2025: Cologuard Plus, Oncodetect, and Cancerguard. These innovations are expected to strengthen its leadership in the diagnostics sector and contribute to future revenue growth, impacting Exact Sciences ownership trends.
Exact Sciences Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Exact Sciences Company?
- What is Competitive Landscape of Exact Sciences Company?
- What is Growth Strategy and Future Prospects of Exact Sciences Company?
- How Does Exact Sciences Company Work?
- What is Sales and Marketing Strategy of Exact Sciences Company?
- What are Mission Vision & Core Values of Exact Sciences Company?
- What is Customer Demographics and Target Market of Exact Sciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.